Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade

Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment

(2016) C. Bender et al.   ANNALS OF ONCOLOGY

Circulating Beta-2 Microglobulin and Risk of Cancer: The Atherosclerosis Risk in Communities Study (ARIC)

(2016) A. E. Prizment et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement

(2016) Rashmi Bharti et al.   CANCER LETTERS

The SRF-YAP-IL6 axis promotes breast cancer stemness

(2016) Tackhoon Kim et al.   CELL CYCLE

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

(2016) A. Martens et al.   CLINICAL CANCER RESEARCH

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Δ133p53 isoform and its mouse analogue Δ122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2

(2016) I Roth et al.   ONCOGENE

Self-renewal of CD133hi cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer

(2016) Pasquale Sansone et al.   Nature Communications

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

(2015) Santiago Zelenay et al.   CELL

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab

(2015) S. Valpione et al.   EUROPEAN JOURNAL OF CANCER

C-Reactive Protein As a Marker of Melanoma Progression

(2015) Shenying Fang et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

Ipilimumab in the real world

(2015) Saif S. Ahmad et al.   MELANOMA RESEARCH

IL6 Mediates Immune and Colorectal Cancer Cell Cross-talk via miR-21 and miR-29b

(2015) S. A. A. Patel et al.   MOLECULAR CANCER RESEARCH

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in ovarian cancer cells

(2015) Minghua Zou et al.   CELLULAR ONCOLOGY

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

(2015) Aitziber Buqué et al.   OncoImmunology

A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma

(2015) Nicole Marie Agostino et al.   SpringerPlus

Economic Burden Associated with Adverse Events in Patients with Metastatic Melanoma

(2015) Bhakti Arondekar et al.   Journal of Managed Care & Specialty Pharmacy

Correcting for Optimistic Prediction in Small Data Sets

(2014) Gordon C. S. Smith et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

(2014) C. Lebbe et al.   ANNALS OF ONCOLOGY

Interleukin-6 and its receptors: A highly regulated and dynamic system

(2014) Janina Wolf et al.   CYTOKINE

Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations

(2014) Desirée Schubert et al.   NATURE MEDICINE

Somatic Mutations and Immunotherapy Outcome with CTLA-4 Blockade in Melanoma

(2014) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)

(2013) D. McDermott et al.   ANNALS OF ONCOLOGY

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

The Use of Cytokines and Chemokines in the Cancer Immunotherapy

(2013) Amedeo Amedei et al.   Recent Patents on Anti-Cancer Drug Discovery

Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma

(2012) Lise Hoejberg et al.   MELANOMA RESEARCH

Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis

(2012) Victor Barzey et al.   JOURNAL OF MEDICAL ECONOMICS

Beta2-Microglobulin Can Be a Disease Activity Marker in Systemic Lupus Erythematosus

(2010) Hyoun-Ah Kim et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Biomarkers in melanoma

(2009) H. Gogas et al.   ANNALS OF ONCOLOGY